The beneficial effects of the SGLT2 inhibitors on CV outcomes, including CV mortality and decreased rate of heart failure admissions, is a major progress in the treatment of patients with diabetes (4,5). This evidence concerns the gene SLC5A2 and diabetes mellitus.